Atehsa Sahagun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Atehsa Sahagun has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Helen S. Bateup
Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, USA
4 shared publications - Dirk Hockemeyer
Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, USA
3 shared publications - Donald C. Rio
Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, USA
3 shared publications - Frank Soldner
Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, Rose F. Kennedy Center, Albert Einstein College of Medicine
3 shared publications - Jesse Dunnack
Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, USA
3 shared publications - Khaja Mohieddin Syed
Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, USA
3 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
iSCORE-PD: an isogenic stem cell collection to research Parkinson’s disease
Genome-edited human pluripotent stem cells (hPSCs) provide a powerful platform to study complex diseases such as Parkinson’s disease (PD). Here, we describe iSCORE-PD, an isogenic collection of 65 genome-edited hPSC lines carrying disease-causing or high-risk variants in 11 PD-linked genes ( SNCA, PRKN, PINK1, DJ1/PARK7, LRRK2, ATP13A2, FBXO7, DNAJC6, SYNJ1, VPS13C , and GBA1 ). All lines are derived from a well-characterized female hESC line and subjected to extensive quality control. Whole-genome sequencing reveals that genetic variation between lines, largely confined to non-coding regions, is minimal relative to inter-individual differences in patient-derived hiPSCs, with most variation arising from random mutations acquired during cell culture rather than genome-editing-induced off-target effects. Including multiple independently derived clones per mutation can control for this random genetic drift. Our systematic approach ensures high quality of this publicly available iSCORE-PD resource, highlights the advantages of prime editing over conventional CRISPR/Cas9 methods, and establishes best practices for generating disease-modeling hPSC collections.
- 17 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessiSCORE-PD: an isogenic stem cell collection to research Parkinson’s disease
Genome-edited human pluripotent stem cells (hPSCs) provide a powerful platform to study complex diseases such as Parkinson’s disease (PD). Here, we describe iSCORE-PD, an isogenic collection of 65 genome-edited hPSC lines carrying disease-causing or high-risk variants in 11 PD-linked genes ( SNCA, PRKN, PINK1, DJ1/PARK7, LRRK2, ATP13A2, FBXO7, DNAJC6, SYNJ1, VPS13C , and GBA1 ). All lines are derived from a well-characterized female hESC line and subjected to extensive quality control. Whole-genome sequencing reveals that genetic variation between lines, largely confined to non-coding regions, is minimal relative to inter-individual differences in patient-derived hiPSCs, with most variation arising from random mutations acquired during cell culture rather than genome-editing-induced off-target effects. Including multiple independently derived clones per mutation can control for this random genetic drift. Our systematic approach ensures high quality of this publicly available iSCORE-PD resource, highlights the advantages of prime editing over conventional CRISPR/Cas9 methods, and establishes best practices for generating disease-modeling hPSC collections.
- Open Access
An isogenic single-cell atlas of familial Parkinson’s disease mutations reveals convergent changes in dopamine neurons
Summary/ Familial Parkinson’s disease (PD) is caused by mutations in more than twenty genes that affect diverse cellular pathways, including mitochondrial quality control, lysosomal function, and vesicular trafficking. A central question is how mutations impacting these distinct pathways converge to cause the selective degeneration of dopamine neurons. Human pluripotent stem cell (hPSC)-based disease models provide a valuable system to study this; however, systematic comparison of the pathogenic effects of different mutations has been limited by genetic background variability. To address this, we generated an isogenic single-cell transcriptomic atlas of fourteen familial PD mutations comprising more than 200,000 hPSC-derived midbrain specified cells. Integrated analysis revealed mutation-specific transcriptional signatures alongside shared dysregulated genes and modules that converge on mitochondrial homeostasis, endolysosomal degradation, and iron/ferroptosis pathways. Differentially expressed genes were significantly enriched for PD GWAS-implicated genes in dopamine neurons, bridging monogenic and sporadic PD genetic risk and highlighting a shared downstream state across multiple mutations. Finally, cells with a DNAJC6 mutation, which is associated with juvenile-onset parkinsonism, exhibited alteration of neurodevelopmental and psychiatric disorder risk genes, providing a transcriptional correlate for neurodevelopmental features observed in early-onset PD. Together, this resource enables molecular stratification of familial PD mutations and provides a foundational benchmarking data set.
Open AccessAn isogenic single-cell atlas of familial Parkinson’s disease mutations reveals convergent changes in dopamine neurons
Summary/ Familial Parkinson’s disease (PD) is caused by mutations in more than twenty genes that affect diverse cellular pathways, including mitochondrial quality control, lysosomal function, and vesicular trafficking. A central question is how mutations impacting these distinct pathways converge to cause the selective degeneration of dopamine neurons. Human pluripotent stem cell (hPSC)-based disease models provide a valuable system to study this; however, systematic comparison of the pathogenic effects of different mutations has been limited by genetic background variability. To address this, we generated an isogenic single-cell transcriptomic atlas of fourteen familial PD mutations comprising more than 200,000 hPSC-derived midbrain specified cells. Integrated analysis revealed mutation-specific transcriptional signatures alongside shared dysregulated genes and modules that converge on mitochondrial homeostasis, endolysosomal degradation, and iron/ferroptosis pathways. Differentially expressed genes were significantly enriched for PD GWAS-implicated genes in dopamine neurons, bridging monogenic and sporadic PD genetic risk and highlighting a shared downstream state across multiple mutations. Finally, cells with a DNAJC6 mutation, which is associated with juvenile-onset parkinsonism, exhibited alteration of neurodevelopmental and psychiatric disorder risk genes, providing a transcriptional correlate for neurodevelopmental features observed in early-onset PD. Together, this resource enables molecular stratification of familial PD mutations and provides a foundational benchmarking data set.
- Open Access
- 8 December 2025
- Published by Springer Nature in Nature
- Vol. 649 (8095) , E2
Publisher Correction: CRISPR activation for SCN2A-related neurodevelopmental disorders
- 8 December 2025
- Published by Springer Nature in Nature
- Vol. 649 (8095) , E2
Open AccessPublisher Correction: CRISPR activation for SCN2A-related neurodevelopmental disorders
- Open Access
- 21 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 9314
Gastrin-releasing peptide signaling in the nucleus accumbens medial shell regulates neuronal excitability and motivation
Neuropeptides are the largest class of neuromodulators. It has been shown that subpopulations of ventral tegmental area (VTA) dopamine neurons express mRNA for the neuropeptide Gastrin-releasing peptide (GRP); however, its functional relevance in mesolimbic circuits is unknown. Here we report that the GRP receptor (GRPR) is expressed in nucleus accumbens medial shell (NAc MSh) neurons, which are targeted by GRP-expressing inputs from the VTA, hippocampus, and amygdala. We show that NAc MSh GRPR-positive cells represent subpopulations of D2 receptor-expressing neurons, comprising both classical striatal projection neurons (SPNs) and eccentric SPNs. GRPR-expressing neurons have high intrinsic excitability and can be activated by GRP in vivo. NAc-specific deletion of Grpr in mice increases motivation in a progressive ratio test, demonstrating that GRPR regulates motivated behaviors. These experiments establish GRP/GRPR signaling as a potent modulator of mesolimbic circuits and advance our understanding of the diversity of cell types present in the NAc.
- 21 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 9314
Open AccessGastrin-releasing peptide signaling in the nucleus accumbens medial shell regulates neuronal excitability and motivation
Neuropeptides are the largest class of neuromodulators. It has been shown that subpopulations of ventral tegmental area (VTA) dopamine neurons express mRNA for the neuropeptide Gastrin-releasing peptide (GRP); however, its functional relevance in mesolimbic circuits is unknown. Here we report that the GRP receptor (GRPR) is expressed in nucleus accumbens medial shell (NAc MSh) neurons, which are targeted by GRP-expressing inputs from the VTA, hippocampus, and amygdala. We show that NAc MSh GRPR-positive cells represent subpopulations of D2 receptor-expressing neurons, comprising both classical striatal projection neurons (SPNs) and eccentric SPNs. GRPR-expressing neurons have high intrinsic excitability and can be activated by GRP in vivo. NAc-specific deletion of Grpr in mice increases motivation in a progressive ratio test, demonstrating that GRPR regulates motivated behaviors. These experiments establish GRP/GRPR signaling as a potent modulator of mesolimbic circuits and advance our understanding of the diversity of cell types present in the NAc.
- Top Cited Papers
- 17 September 2025
- Published by Springer Nature in Nature
- Vol. 646 (8086) , 983-991
CRISPR activation for SCN2A-related neurodevelopmental disorders
Most neurodevelopmental disorders with single gene diagnoses act via haploinsufficiency, in which only one of the two gene copies is functional1. SCN2A haploinsufficiency is one of the most frequent causes of neurodevelopmental disorder, often presenting with autism spectrum disorder, intellectual disability and, in a subset of children, refractory epilepsy2. Here, using SCN2A haploinsufficiency as a proof-of-concept, we show that upregulation of the existing functional gene copy through CRISPR activation (CRISPRa) can rescue neurological-associated phenotypes in Scn2a haploinsufficient mice. We first show that restoring Scn2a expression in adolescent heterozygous Scn2a conditional knock-in mice rescues electrophysiological deficits associated with Scn2a haploinsufficiency (Scn2a+/−). Next, using an adeno-associated virus CRISPRa-based treatment in adolescent mice, we show that we can correct intrinsic and synaptic deficits in neocortical pyramidal cells, a major cell type that contributes to neurodevelopmental disorders and seizure aetiology in SCN2A haploinsufficiency. Furthermore, we find that systemic delivery of CRISPRa protects Scn2a+/− mice against chemoconvulsant-induced seizures. Finally, we also show that adeno-associated virus CRISPRa treatment rescues excitability in SCN2A haploinsufficient human stem-cell-derived neurons. Our results showcase the potential of this therapeutic approach to rescue SCN2A haploinsufficiency and demonstrates that rescue even at adolescent stages can ameliorate neurodevelopmental phenotypes.
- 17 September 2025
- Published by Springer Nature in Nature
- Vol. 646 (8086) , 983-991
Top Cited PapersCRISPR activation for SCN2A-related neurodevelopmental disorders
Most neurodevelopmental disorders with single gene diagnoses act via haploinsufficiency, in which only one of the two gene copies is functional1. SCN2A haploinsufficiency is one of the most frequent causes of neurodevelopmental disorder, often presenting with autism spectrum disorder, intellectual disability and, in a subset of children, refractory epilepsy2. Here, using SCN2A haploinsufficiency as a proof-of-concept, we show that upregulation of the existing functional gene copy through CRISPR activation (CRISPRa) can rescue neurological-associated phenotypes in Scn2a haploinsufficient mice. We first show that restoring Scn2a expression in adolescent heterozygous Scn2a conditional knock-in mice rescues electrophysiological deficits associated with Scn2a haploinsufficiency (Scn2a+/−). Next, using an adeno-associated virus CRISPRa-based treatment in adolescent mice, we show that we can correct intrinsic and synaptic deficits in neocortical pyramidal cells, a major cell type that contributes to neurodevelopmental disorders and seizure aetiology in SCN2A haploinsufficiency. Furthermore, we find that systemic delivery of CRISPRa protects Scn2a+/− mice against chemoconvulsant-induced seizures. Finally, we also show that adeno-associated virus CRISPRa treatment rescues excitability in SCN2A haploinsufficient human stem-cell-derived neurons. Our results showcase the potential of this therapeutic approach to rescue SCN2A haploinsufficiency and demonstrates that rescue even at adolescent stages can ameliorate neurodevelopmental phenotypes.
- Open Access
iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease
Parkinson’s disease (PD) is a neurodegenerative disorder caused by complex genetic and environmental factors. Genome-edited human pluripotent stem cells (hPSCs) offer a unique experimental platform to advance our understanding of PD etiology by enabling the generation of disease-relevant cell types carrying patient mutations along with isogenic control cells. To facilitate this approach, we generated a collection of 65 human stem cell lines genetically engineered to harbor high risk or causal variants in genes associated with PD ( SNCA A53T, SNCA A30P, PRKN Ex3del, PINK1 Q129X, DJ1/PARK7 Ex1-5del, LRRK2 G2019S, ATP13A2 FS, FBXO7 R498X/FS, DNAJC6 c.801 A>G/FS, SYNJ1 R258Q/FS, VPS13C A444P/FS, VPS13C W395C/FS, GBA1 IVS2+1/FS). All mutations were introduced into a fully characterized and sequenced female human embryonic stem cell (hESC) line (WIBR3; NIH approval number NIHhESC-10-0079) using different genome editing techniques. To ensure the genetic integrity of these cell lines, we implemented rigorous quality controls, including whole-genome sequencing of each line. Our analysis of the genetic variation in this cell line collection revealed that while genome editing, particularly using CRISPR/Cas9, can introduce rare off-target mutations, the predominant source of genetic variants arises from routine cell culture and are fixed in cell lines during clonal isolation. The observed genetic variation was minimal compared to that typically found in patient-derived iPSC experiments and predominantly affected non-coding regions of the genome. Importantly, our analysis outlines strategies for effectively managing genetic variation through stringent quality control measures and careful experimental design. This systematic approach ensures the high quality of our stem cell collection, highlights advantages of prime editing over conventional CRISPR/Cas9 methods and provides a roadmap for the generation of gene-edited hPSC collections at scale in an academic setting. Our iSCORE-PD collection represents an easily accessible and valuable platform to study PD, which can be used by investigators to understand the molecular pathophysiology of PD in a human cellular setting.
Open AccessiSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease
Parkinson’s disease (PD) is a neurodegenerative disorder caused by complex genetic and environmental factors. Genome-edited human pluripotent stem cells (hPSCs) offer a unique experimental platform to advance our understanding of PD etiology by enabling the generation of disease-relevant cell types carrying patient mutations along with isogenic control cells. To facilitate this approach, we generated a collection of 65 human stem cell lines genetically engineered to harbor high risk or causal variants in genes associated with PD ( SNCA A53T, SNCA A30P, PRKN Ex3del, PINK1 Q129X, DJ1/PARK7 Ex1-5del, LRRK2 G2019S, ATP13A2 FS, FBXO7 R498X/FS, DNAJC6 c.801 A>G/FS, SYNJ1 R258Q/FS, VPS13C A444P/FS, VPS13C W395C/FS, GBA1 IVS2+1/FS). All mutations were introduced into a fully characterized and sequenced female human embryonic stem cell (hESC) line (WIBR3; NIH approval number NIHhESC-10-0079) using different genome editing techniques. To ensure the genetic integrity of these cell lines, we implemented rigorous quality controls, including whole-genome sequencing of each line. Our analysis of the genetic variation in this cell line collection revealed that while genome editing, particularly using CRISPR/Cas9, can introduce rare off-target mutations, the predominant source of genetic variants arises from routine cell culture and are fixed in cell lines during clonal isolation. The observed genetic variation was minimal compared to that typically found in patient-derived iPSC experiments and predominantly affected non-coding regions of the genome. Importantly, our analysis outlines strategies for effectively managing genetic variation through stringent quality control measures and careful experimental design. This systematic approach ensures the high quality of our stem cell collection, highlights advantages of prime editing over conventional CRISPR/Cas9 methods and provides a roadmap for the generation of gene-edited hPSC collections at scale in an academic setting. Our iSCORE-PD collection represents an easily accessible and valuable platform to study PD, which can be used by investigators to understand the molecular pathophysiology of PD in a human cellular setting.